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See Article, pages 309–317The constantly enlarging waiting lists for patients with hepato-
cellular carcinoma (HCC) referred for liver transplantation (LT)
has been a driving force for development of improved loco-
regional as well as systemic treatment modalities. Tumour pro-
gression after enlisting of patients for LT using the Milan criteria
may vary between 10% and 23% and more, while delisting is a rel-
atively frequent consequence [1]. Furthermore, a large number of
patients present with tumour burden beyond the even extended
Milan criteria. Tumour down-staging of such patients pending
resection or as a bridge to LT has been repeatedly suggested using
transarterial chemoembolization (TACE), radiofrequency ablation
(RF), radioembolization (RE), external beam irradiation, and even
systemic treatment with sorafenib [2–5]. At present, information
regarding the relative efﬁcacy, tolerability, and safety of one
loco-regional modality over the other or vs. the standard of care
treatment with sorafenib in deﬁned BCLC stages is mainly
derived from retrospective and/or non-randomized clinical trials
(for example [6–8]). Indeed, comparative prospective, random-
ized phase III clinical trials of the available treatment options
for HCC are extremely difﬁcult to conduct due to the heteroge-
neous biologic properties of tumours and hosts, the impact of
intervention such as LT, as well as the requirement for a long
follow-up and a very large study population [9,10].
In this context, treatment with Yttrium-90 (90Y) radio-embo-
lization (RE) using either resin or glass microsphere injection into
the hepatic artery, has been at the focus of attention among hep-
atologists, oncologists, and invasive radiologists for more than a
decade [11–13]. It has been evaluated in phase I and phase II clin-
ical trials for patients with advanced hepatocellular carcinoma
(HCC) demonstrating acceptable safety as well as promising efﬁ-
cacy and has been suggested as a mean for down-staging HCC
pending liver transplantation in patients with intermediate and
advanced disease including those with portal vein invasion.
Exposure to the beta emission released by Yttrium 90 radiation
(t/2 2.67 days), leads to endothelial, tumour, and stromal cell
injury and cell death. However, to quote from the 2012 EASLJournal of Hepatology 20
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Open access under CC BY-NC-ND license.guidelines on treatment of HCC: ‘‘Cohort studies reporting long-
term outcomes showed a median survival time of 17.2 months
for patients at intermediate stages and 12 months for patients
at advanced stages and portal vein invasion. Objective response
rates range from 35% to 50%. Around 20% of patients present
liver-related toxicity and 3% treatment-related death. Despite
the amount of data reported, there are no randomized controlled
trials (RCT) testing the efﬁcacy of 90Y radioembolization com-
pared with chemoembolization or sorafenib in patients at inter-
mediate or advanced stage, respectively. Further research trials
are needed to establish a competitive efﬁcacy role in these pop-
ulations’’ [14]. The lack of evidence obtained from phase III RCTs
using RE mentioned in the 2012 EASL HCC guidelines is about to
change and at least 6 RCTs comparing RE to transarterial chemo-
embolization (TACE) or sorafenib are in progress with estimated
completion between 2014 and 2018 [12].
One rational for adding sorafenib to RE or TACE is based on the
assumption that this neo-adjuvant will attenuate the ﬂush of
angiogenic factors (i.e., VEGF) released following arterial emboli-
zation and hypoxia.
In the present issue of the journal, Kulik and co-workers from
the Northwestern University in Chicago, report the results of a
ﬁrst and small prospective randomized pilot study evaluating
the safety and adverse events of 90Y RE administered with or
without Sorafenib in HCC patients awaiting liver transplantation
[15]. This report complements a recent paper by the same group
evaluating the radiological and pathological changes observed in
the same group of patients receiving either monotherapy with RE
or combined 90Y and sorafenib treatment as a bridge to liver
transplantation [16].
The study population consisted originally of 23 patients with
conﬁrmed HCC either through imaging criteria or histology. After
exclusion of 3 patients, 20 candidate patients for liver transplan-
tation (the majority with chronic hepatitis C) were prospectively
randomized to receive either RE monotherapy (using Thera-
Sphere, BTG, Canada) or sorafenib with 90Y RE. In the combina-
tion group, sorafenib, 400 mg twice daily, was started 14 days
prior to RE and continued for up to 12 months and discontinued
once the patient reached the number 1 position on the LT waiting
list. The sorafenib dose was adjusted throughout the treatment
period according to toxicity. The majority of patients had14 vol. 61 j 190–192
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unilobar and unifocal tumours (n = 18). Median lesion diameter
was 2.9 cm (range 1.7–5.6 cm) and 3.3 cm (1.1–4.5) for the 90Y
alone and the combined RE and sorafenib group respectively,
most of them being classiﬁed as T2 UNOS stage. The baseline bio-
logical proﬁle as determined by blood count, INR and creatinine
levels was similar for both groups except for somewhat lower
albumin and higher total bilirubin levels in the RE monotherapy
group. Most patients underwent one session of RE except for 2
patients in the RE monotherapy group who received one and
two additional RE treatments and one was also treated by TACE.
In the combination group, three patients received one or more
additional RE treatments as well as TACE or RFA. The small sam-
ple size of this study and relatively short follow-up period post
transplantation (median follow-up 29.9 months) do not enable
an assessment of comparative efﬁcacy of the different pre-trans-
plant treatment modalities. Yet, the data obtained prospectively
in this pilot study, provide some preliminary information regard-
ing the safety and tolerability of the treatment regimens and not
less important, reiterate the difﬁculty in conducting prospective
clinical trials in this difﬁcult group of HCC patients.
Comments: The main results observed before LT include abso-
lute grade 3–4 lymphotoxicity which was more pronounced in
the RE monotherapy group. A rise in total bilirubin was equally
distributed between both groups with a statistically non-signiﬁ-
cant trend of higher levels in the monotherapy group. Fatigue
and abdominal pain were statistically more frequent in the
monotherapy RE arm affecting 65% and 25% of patients respec-
tively. Yet, the signiﬁcance of these pre-transplant observations
seems marginal and the true magnitude and biologic implications
of these phenomena in this small group of patients remain to be
determined. Seventeen patients underwent LT, one underwent
liver resection and two died of HCC progression or sepsis prior
to transplantation. Two patients in the monotherapy RE and
one patients in the combined group died 49–970 days post LT.
Survival rates were similar for both groups reaching 70%.
Two important observations from this study require special
attention: First, all 10 patients in the combined 90Y RE and sorafe-
nib group could not tolerate the initially prescribed dose of
sorafenib. Consequently, sorafenib dosing was not optimal and
only 3/10 patients received reduced doses of sorafenib until close
to LT. Moreover, 50% of patients discontinued sorafenib alto-
gether following side effects (described in detail in the report).
Second, biliary complications (mainly due to anastomotic
strictures) and acute cellular rejection were observed within
30 days post LT, in 2/8 and 3/8 patients respectively, treated with
the combination of sorafenib and RE prior to LT. In contrast, no
such biliary complications or acute rejection were present in
the RE monotherapy group.
These two observations raise the question whether the pre-
transplant intolerance to sorafenib and the post-transplant bili-
ary complications and rejection signify a safety signal regarding
sorafenib therapy as a neo-adjuvant in patients receiving RE.
Doubts regarding the usefulness of adding sorafenib to RE in
patients not referred for LT, have already risen following a retro-
spective analysis of a small study in which 10 HCC patients with
BCLC stage C were treated with sorafenib prior to RE [17]. In this
study, overall survival of patients with advanced HCC receiving a
combination of RE and sorafenib was lower compared to histori-
cal data in patients treated with RE or sorafenib alone. A recent,
much larger retrospective, single center study compared the sur-
vival and safety of RE (n = 63 patients) with sorafenib (n = 74) [7].Journal of Hepatology 201Median overall survival of the two groups was similar reaching
14.4 months and 13.2 months in the sorafenib and RE group
respectively. Median time to progression was signiﬁcantly longer
in the sorafenib group reaching 5 months compared to 3 months
in the RE group. However, treatment was down dosed in 56/74 of
patients (52 for sorafenib associated adverse events) while the RE
patients tolerated treatment much better. Taking into account
that sorafenib treatment did not augment the anti-tumoural
effect of 90Y as reported recently for the same cohort of patients
[15]; the poor tolerability of sorafenib described in retrospective
and as well as the current prospective studies; and the limita-
tions of the discussed study as accurately described by the
authors, it is very doubtful that sorafenib should be utilized as
a neo-adjuvant for patients treated with RE. It is noteworthy that
RE is gradually accepted as a valid loco-regional treatment
modality worldwide despite the criticism regarding lack of objec-
tive evidence obtained through prospective phase III multicentre
randomized trials comparing RE to other ablation modalities or
sorafenib [10,14]. This study by Kulik et al. is indeed the ﬁrst such
prospective and randomized effort and this active group of inves-
tigators should be commended for this effort. However, the
adverse events reported so far, the need in down dosing or dis-
continuation of sorafenib and the energy involved even in this
very small study as well as the difﬁculties in recruitment and fol-
low-up of HCC patients over a long period of time [9] cast doubt
whether such an effort should be made to prove the additional
and very doubtful beneﬁt of sorafenib as a neo-adjuvant to RE.Conﬂict of interest
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